SCHEDULE: Edesa Biotech Insider Boosts Stake to 19.99%

Dr. Pardeep Nijhawan and affiliated entities have increased their beneficial ownership in Edesa Biotech, Inc. to 19.99% through recent share purchases and RSU grants.

Summary

• Dr. Pardeep Nijhawan and his affiliated entities now beneficially own an aggregate of 2,040,785 Common Shares of Edesa Biotech, Inc., representing 19.99% of the outstanding class.
• This ownership includes shares held directly by Dr. Nijhawan, as well as through Pardeep Nijhawan Medicine Professional Corporation, The Digestive Health Clinic Inc., 1968160 Ontario Inc., and The New Nijhawan Family Trust 2015.
• Since February 14, 2025, Dr. Nijhawan received multiple restricted stock unit (RSU) grants, totaling 175,634 RSUs that vested upon grant, primarily in lieu of partial salary and bonus.
• An additional 263,200 RSUs were granted to Dr. Nijhawan on May 29, 2025, with vesting scheduled over 12 and 36 months.
• On February 26, 2026, Dr. Pardeep Nijhawan personally purchased 20,571 Common Shares at a weighted average price of $1.5789 per share for an aggregate of $32,479.34.
• On the same date, Pardeep Nijhawan Medicine Professional Corporation purchased 30,000 Common Shares at a weighted average price of $2.2232 per share for an aggregate of $66,695.00.
• The reporting persons acquired these securities for investment purposes, based on their belief in the Issuer's business prospects and strategy.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, as increased insider ownership, especially through direct purchases, typically reflects management's confidence in the company's future prospects.

Positives

• Increased insider ownership by Dr. Pardeep Nijhawan and affiliated entities, signaling confidence in the company's future.
• Recent share purchases by Dr. Nijhawan and his professional corporation demonstrate a direct financial commitment to the company.
• The acquisition of securities is stated to be for investment in the ordinary course of business, based on belief in the Issuer's business prospects and strategy.

Risks

• The reporting persons reserve the right to dispose of securities at any time, which could lead to selling pressure on the stock.
• The 19.99% beneficial ownership blocker on Series B-1 Preferred Shares limits Dr. Nijhawan's immediate ability to convert these shares if it would exceed the threshold, potentially impacting liquidity or control.

Future Outlook

The reporting persons acquired the securities for investment, based on their belief in the Issuer's business prospects and strategy, and reserve the right to acquire or dispose of additional securities or formulate other plans regarding the Issuer.

Management Comments

• "The Reporting Persons acquired the securities reported herein for investment in the ordinary course of business because of their belief that the Issuer represents an attractive investment based on the Issuer's business prospects and strategy."
• "The Reporting Persons reserve the right to acquire, or cause to be acquired, additional securities of the Issuer, to dispose of, or cause to be disposed of, such securities at any time or to formulate other purposes, plans or proposals regarding the Issuer or any of its securities, to the extent deemed advisable in light of general investment and trading policies of the Reporting Persons, market conditions or other factors."

Industry Context

StockSavvy.ai notes that increased insider ownership, especially by a key executive like Dr. Pardeep Nijhawan, often signals strong internal confidence in a company's future performance, which can be a positive indicator for investors in the biotech sector, where long-term development and strategic vision are crucial.

Comparison to Industry Standards

• Insider buying, particularly by a CEO, is generally viewed positively across industries as it aligns management's interests with shareholders. For biotech companies, where R&D cycles are long and capital intensive, such a commitment can be particularly reassuring.
• While specific comparable companies are not mentioned in the filing, similar insider purchases have been observed in other small-cap biotech firms like XBiotech Inc. (XBIT) or Sorrento Therapeutics (SRNEQ) where management's personal investment often precedes significant clinical or commercial milestones.
• The accumulation to just under 20% is a common threshold in U.S. securities law (triggering Schedule 13D), and maintaining this level suggests a strategic long-term stake without triggering certain control-related provisions that might apply at higher ownership percentages.

Related Party Transactions

• Dr. Pardeep Nijhawan received multiple restricted stock unit grants, some in lieu of partial salary and bonus, from the Issuer.
• Dr. Pardeep Nijhawan and his affiliated entities (Pardeep Nijhawan Medicine Professional Corporation, The Digestive Health Clinic Inc., 1968160 Ontario Inc., The New Nijhawan Family Trust 2015) are considered related parties due to his control and significant beneficial ownership, and their transactions are disclosed herein.

Stakeholder Impact

• Shareholders: Increased insider ownership may instill confidence, potentially leading to positive sentiment. However, the reservation of rights to dispose of shares introduces potential future selling pressure.
• Management/Employees: Dr. Nijhawan's continued accumulation of shares and receipt of RSUs aligns his interests more closely with the company's long-term success.

Next Steps

• The reporting persons may acquire or dispose of additional securities of the Issuer.
• The reporting persons may formulate other purposes, plans, or proposals regarding the Issuer or its securities.
• Ongoing vesting of 263,200 restricted stock units granted on May 29, 2025, over 12 and 36 months.

Key Dates

Recommendation

The increased insider ownership by Dr. Pardeep Nijhawan and his affiliates, including recent direct share purchases, signals strong confidence in Edesa Biotech's future. This is generally a positive indicator. However, without additional operational or financial updates from the company, this filing primarily reflects an ownership adjustment rather than a fundamental change in business prospects. Investors should hold their positions and monitor for further company developments that would justify a stronger buy recommendation.

Keywords

Edesa Biotech, EDSA, Schedule 13D/A, Beneficial Ownership, Insider Buying, Pardeep Nijhawan, Restricted Stock Units, Common Shares, Investment, Biotech